Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
about
Alemtuzumab in clinical practice: a British Columbia experience.A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.Plitidepsin has a safe cardiac profile: a comprehensive analysis.Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemiaSkin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.Emerging drugs in cutaneous T-cell lymphomas.Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantationStandard and experimental therapy in cutaneous T-cell lymphomas.Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 studyCardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged SwordAlemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.Alemtuzumab in the treatment of chronic lymphocytic lymphoma.Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).Introducing a new entity: chemotherapy-induced arrhythmia.Induction immunosuppression for orthotopic heart transplantation: a review.Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.Chemotherapy-induced cardiomyopathy.Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.Cancer chemotherapy and cardiac arrhythmias: a review.Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms
P2860
Q33378464-2C503088-0C07-4D48-9E96-D0D375BC0031Q33388189-2280A6E0-E33A-4BBB-A869-D28C8711AF29Q33807542-CDA3049A-F8FC-4B06-A955-29BAFF013581Q34222228-1314E6E5-DECF-4D7F-9FF1-49C71502F100Q34571555-30421982-7F34-4738-97EA-20361A9299CAQ35091717-F9FC6A4E-292B-446F-9CA8-9EDD537F8D0EQ35669193-8C36F09D-4EE7-4EF1-9C6E-21F825C0E6CCQ36026719-089C6188-26AA-4878-AF19-975854C52015Q36150634-8F9F4FAE-5297-4C55-95A8-739DC4AA8F6DQ36176670-3C836248-C33C-45AD-8532-A9230ED6DB37Q36367929-1F2B599B-21E9-4A4C-A046-7B5CBE3043F1Q36486302-1D3AA1DE-0887-409F-B6C1-EE1270CDA1EBQ36721511-79274487-2C56-4F3C-9267-8D22B8D77F18Q36832113-90D8E498-CFAC-442B-ACF7-3F0AEEDD9CA5Q37134417-50CFE66B-3F43-4DBB-91FB-5E1390F8EF76Q37203741-3D1229D1-B691-49B4-B37A-3FB9038C7910Q37307583-9253E52B-40EB-4035-9B7A-BC67A3529C3AQ37607920-21E4B2F8-6119-448C-AFED-DA3F179E502EQ37668566-4CF93D10-2110-4DBE-BABA-50AD23E0E04AQ37810272-068EC65A-24B0-4B4D-BC3C-C8A6416E9076Q37854494-6DF68F39-85CB-4C10-8BBD-AEC2B736F69EQ37867085-6A4217FF-55CE-482C-A460-51689A44D07CQ37998019-3E25F027-2796-449F-B920-74D4390B84D2Q38126946-BF9E8A62-8723-458C-96F8-99E419AC1CBAQ38313870-224F2084-F64C-4078-9D39-47EF387C3A8BQ38508938-ED5706BC-627A-4439-A679-D38D7C414AA4Q38944823-AD391DA4-6BC4-418D-97FD-8B069CAE5E12Q39532967-44E078D8-6BB6-4962-B44A-BAB3B111FC8FQ42908395-EA6DF080-7548-4752-A92F-B96FB1E1D24FQ58554222-28CA3770-8183-4DC7-B4DC-4E614B58BD21
P2860
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
@ast
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
@en
type
label
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
@ast
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
@en
prefLabel
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
@ast
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
@en
P2093
P1433
P1476
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
@en
P2093
Alvaro J Alencar
Daniel J Lenihan
Deborah Yang
Madeleine Duvic
P304
P356
10.1182/BLOOD-2003-07-2345
P407
P577
2004-04-08T00:00:00Z